InflaRx NV
IFRX
查看详细走势图
0.840USD
-0.072-7.93%
交易中 （美东）报价延迟15分钟
19.66M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-7.93%
5天
-10.68%
1月
-8.74%
6月
-38.72%
今年开始到现在
-16.87%
1年
-26.99%
查看详细走势图
TradingKey InflaRx NV股票评分
单位: USD 更新时间: 2026-03-27操作建议
InflaRx NV当前公司基本面数据相对稳定，最新ESG披露属于行业领先水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名145/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价8.86。中期看，股价处于下降通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
InflaRx NV评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
中性
InflaRx NV亮点
亮点风险
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
业绩增长期
公司处于发展阶段，最新年度总收入25.31K美元
估值高估
公司最新PE估值-1.58，处于3年历史高位
机构减仓
最新机构持股18.80M股，环比减少19.80%
史蒂文·科恩持仓
明星投资者史蒂文·科恩持仓，最新持仓市值0.00
活跃度增加
近期活跃度增加，过去20天平均换手率0.71
分析师目标
根据
8
位分析师
买入
评级
8.857
目标均价
+852.38%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
InflaRx NV新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
InflaRx NV简介
Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.
公司代码IFRX
公司InflaRx NV
CEORiedemann (Niels C)
网址https://www.inflarx.de/
相关品种
